Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 2, 2008, Pages 156-162

  Mathias, Anita A ^c   Hinkle, John ^c   Shen, Gong ^c   Enejosa, Jeff ^c   Piliero, Peter J ^a   Sekar, Vanitha ^b   Mack, Rebecca ^b   Tomaka, Frank ^b   Kearney, Brian P ^c  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b Tibotec Pharmaceuticals Ltd   (Belgium)

^c GILEAD SCIENCES   (United States)

Author keywords

Darunavir; Elvitegravir; GS 9137; Interaction; Tipranavir

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DARUNAVIR PLUS RITONAVIR; ELVITEGRAVIR; ELVITEGRAVIR PLUS RITONAVIR; RITONAVIR PLUS TIPRANAVIR; UNCLASSIFIED DRUG; DARUNAVIR; PYRIDINE DERIVATIVE; PYRONE DERIVATIVE; QUINOLONE DERIVATIVE; RITONAVIR; SULFONAMIDE; TIPRANAVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NEUROLOGIC DISEASE; NORMAL HUMAN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; DRUG COMBINATION; DRUG INTERACTION; MIDDLE AGED;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIDINES; PYRONES; QUINOLONES; RITONAVIR; SULFONAMIDES;

EID: 55249116493     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318183a982     Document Type: Article

References (25)

1. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of Strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000; 287:646-650.
2. Hazuda DJ, Young SD, Guare JP, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science. 2004;305:528-532.
3. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/ AIDS. Nat Rev Drug Discov. 2005;4:236-248.
4. Sinha S, Grandgenett DP. Recombinant human immunodeficiency virus type 1 integrase exhibits a capacity for full-site integration in vitro that is comparable to that of purified preintegration complexes from virusinfected cells. J Virol. 2005;79:8208-8216.
5. Matsuzaki Y, Watanabe W, Yamataka K, et al. JTK-303/GS-9137, a novel small molecule inhibitor of HIV-1 integrase: anti-HIV activity profile and pharmacokinetics in animals [poster number 508]. Paper presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5-9, 2006; Denver, CO.
6. Ramanathan S, Wright M, West S, et al. Pharmacokinetics, metabolism and excretion of ritonavir-boosted GS-9137 (elvitegravir) [poster number 30]. Presented at: 8th International Workshop on Clinical Pharmacology of HIV Therapy; 2007; Budapest, Hungary.
7. Kearney BP, Mathias A, Zhong L, et al. Pharmacokinetics/pharmacodynamics of GS-9137 an HIV integrase inhibitor in treatment-naïve and experienced patients [abstract 73]. Paper presented at: 7th International Workshop on Clinical Pharmacology of HIV Therapy; April 20-22,2006; Lisbon, Portugal.
8. McCallister S, Sabo J, Mayers D, et al. An open-label steady-state investigation of the pharmacokinetics (PK) of tipranavir (TPV) and ritonavir (RTV) and their effects on cytochrome P-450 (3A4) activity in normal, healthy volunteers. Presented at: 9th Conference on Retroviruses and Opportunistic Infections; 2002; Seattle, WA.
9. Aptivus® (tipranavir) Capsules, 250 mg. US prescribing information [package insert]. Ridgefield, CT. Boehringer Ingelheim. Pharmaceuticals, Inc; Revised June 27, 2006.
10. Hoetelmans R, Van der Sandt I, Pauw MD, et al. TMCl 14, a next generation HIV protease inhibitor: pharmacokinetics and safety following oral administration of multiple doses with and without low doses of ritonavir in healthy volunteers. Presented at: 10th Conference on Retroviruses and Opportunistic Infections; 2003; Hynes Convention Center, Boston, MA.
11. Prezista™ (darunavir) Tablets. US Prescribing Information [package insert]. Tibotec, Inc. Raritan, NJ. Revised October 2006.
12. Ramanathan S, Shen G, Hinkle J, et al. Pharmacokinetic evaluation of drug interactions with ritonavir-boosted HIV integrase inhibitor GS-9137 (elvitegravir) and acid-reducing agents [poster number 69]. Paper presented at: 8th International Workshop on Clinical Pharmacology of HIV Therapy; April 16-18, 2007; Budapest, Hungary.
13. Regulatory Compliance Center. Division of AIDS (DAIDS) Table of Grading Severity of Adult Adverse Experiences. Bethesda, MD: National Institute of Allergy and Infectious Diseases; 1992.
14. Sekar V, De Marez T, Spinosa-Guzman S, et al. Pharmacokinetic interaction between TMC114/ritonavir and atazanavir in healthy volunteers [poster PE4.3/4]. Paper presented at: 10th European AIDS Conference; November 17-20, 2005; Dublin, Ireland.
15. Mukwaya G, MacGregor T, Hoelscher D, et al. Interaction of ritonavirboosted tipranavir with loperamide does not result in loperamideassociated neurologic side effects in healthy volunteers. Antimicrob Agents Chemother. 2005;49:4903-4910.
16. MacGregor TR, Sabo JP, Norris SH, et al. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin Trials. 2004;5:371-382.
17. Levin J. TMC114 PK & drug interactions. Paper presented at: 8th International Congress on Drug Therapy in HIV Infection; 2006; Glasgow, Scotland.
18. Hoetelmans R. Pharmacological exposure and the development of drug resistance in HIV Antivir Ther, 2001;6(Suppl 2):37-47.
19. Shulman N, Zolopa A, Havlir D, et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother. 2002;46:3907-3916.
20. Marcelin AG, Lamotte C, Delaugerre C, et al. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2003;47:594-600.
21. King JR, Acosta EP. Tipranavir: a novel nonpeptidic protease inhibitor of HIV. Clin Pharmacokinet. 2006;45:665-682.
22. Sekar V, Spinosa-Guzman S, Lefebvre E, et al. Clinical pharmacology of TMC114-a new HIV protease inhibitor [abstract TUPE0083]. Presented at: 16th IAS; 2006; Toronto, Canada.
23. Mathias A, West S, Hui J, et al. Effect of increasing ritonavir doses on hepatic CYP3A activity and GS-9137 (elvitegravir) oral exposure. Presented at: 8th International Workshop on Clinical Pharmacology of HIV Therapy [oral presentation]; 2007; Budapest, Hungary.
24. Zhou S, Yung Chan S, Cher Goh B, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005; 44:279-304.
25. Zolopa AR, Mullen M, Berger D, et al. The HIV integrase inhibitor GS9137 has potent antiretroviral activity in treatment-experienced patients [oral presentation 143LB]. Paper presented at: 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA.